Loading patent…
AssigneeUCB Pharma S.A.
InventorsDavid Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenze, Matthew Cox
Estimating the term…
This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
A monoclonal antibody specific to antigen TcdA or TcdB, wherein the antibody has high affinity for the target antigen and is suitable for reducing the duration and/or severity of diarrhoea, morbidity and/or mortality in a patient with Clostridium difficile infection or at risk of said infection.
A method of selecting an antibody mixture for the treatment of Clostridium difficile infections by combining measurements of toxin neutralization, TEER measurements, thermostability measurements (Tm), shaking aggregation measurements and isoelectric point (pI) suitable for coformulation.
Dependencies are inferred from the claim text.